Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...